{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:06:12Z","timestamp":1781625972328,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Changchun GeneScience","award":["This study was funded by Changchun GeneScience."],"award-info":[{"award-number":["This study was funded by Changchun GeneScience."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40262-026-01634-4","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:59:20Z","timestamp":1775750360000},"page":"849-861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2609-6058","authenticated-orcid":false,"given":"Kun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tangping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"issue":"12","key":"1634_CR1","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S2352-4642(23)00237-7","volume":"7","author":"EL Zevin","year":"2023","unstructured":"Zevin EL, Eugster EA. Central precocious puberty: a review of diagnosis, treatment, and outcomes. Lancet Child Adolesc Health. 2023;7(12):886\u201396.","journal-title":"Lancet Child Adolesc Health"},{"issue":"4","key":"1634_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.4274\/jcrpe.v1i4.3","volume":"1","author":"M Berberoglu","year":"2009","unstructured":"Berberoglu M. Precocious puberty and normal variant puberty: definition, etiology, diagnosis and current management. J Clin Res Pediatr Endocrinol. 2009;1(4):164\u201374.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"3","key":"1634_CR3","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/humupd\/7.3.292","volume":"7","author":"CJ Partsch","year":"2001","unstructured":"Partsch CJ, Sippell WG. Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens. Hum Reprod Update. 2001;7(3):292\u2013302.","journal-title":"Hum Reprod Update"},{"key":"1634_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.968485","volume":"10","author":"J Popovic","year":"2022","unstructured":"Popovic J, et al. Gonadotropin-releasing hormone analog therapies for children with central precocious puberty in the United States. Front Pediatr. 2022;10:968485.","journal-title":"Front Pediatr"},{"issue":"2","key":"1634_CR5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.fertnstert.2003.07.013","volume":"81","author":"J Donnez","year":"2004","unstructured":"Donnez J, et al. Equivalence of the 3-month and 28-day formulations of triptorelin with regard to achievement and maintenance of medical castration in women with endometriosis. Fertil Steril. 2004;81(2):297\u2013304.","journal-title":"Fertil Steril"},{"issue":"12","key":"1634_CR6","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1517\/14656566.2013.806489","volume":"14","author":"S Bertelloni","year":"2013","unstructured":"Bertelloni S, Baroncelli GI. Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties. Expert Opin Pharmacother. 2013;14(12):1627\u201339.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1634_CR7","doi-asserted-by":"publisher","first-page":"e752","DOI":"10.1542\/peds.2008-1783","volume":"123","author":"JC Carel","year":"2009","unstructured":"Carel JC, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752\u201362.","journal-title":"Pediatrics"},{"issue":"7","key":"1634_CR8","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/17512433.2018.1494569","volume":"11","author":"S Bertelloni","year":"2018","unstructured":"Bertelloni S, et al. Triptorelin depot for the treatment of children 2 years and older with central precocious puberty. Expert Rev Clin Pharmacol. 2018;11(7):659\u201367.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"1634_CR9","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.fertnstert.2005.03.041","volume":"84","author":"F Massart","year":"2005","unstructured":"Massart F, et al. Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children. Fertil Steril. 2005;84(3):719\u201324.","journal-title":"Fertil Steril"},{"key":"1634_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1170025","volume":"11","author":"M Valenzise","year":"2023","unstructured":"Valenzise M, et al. Leuprolide and triptorelin treatment in children with idiopathic central precocious puberty: an efficacy\/tolerability comparison study. Front Pediatr. 2023;11:1170025.","journal-title":"Front Pediatr"},{"issue":"2","key":"1634_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1590\/2359-3997000000144","volume":"60","author":"VN Brito","year":"2016","unstructured":"Brito VN, et al. Central precocious puberty: revisiting the diagnosis and therapeutic management. Arch Endocrinol Metab. 2016;60(2):163\u201372.","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"1634_CR12","first-page":"16","volume":"61","author":"Subspecialty Group of Endocrinologic, H.","year":"2023","unstructured":"Subspecialty Group of Endocrinologic, H., t.S.o.P.C.M.A. Metabolic Diseases, C.J.o.P. Editorial Board. [Expert consensus on the diagnosis and treatment of central precocious puberty(2022)]. Zhonghua Er Ke Za Zhi. 2023;61(1):16\u201322.","journal-title":"Zhonghua Er Ke Za Zhi"},{"issue":"12","key":"1634_CR13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0243212","volume":"15","author":"YS Shim","year":"2020","unstructured":"Shim YS, et al. Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty. PLoS ONE. 2020;15(12):e0243212.","journal-title":"PLoS ONE"},{"issue":"2","key":"1634_CR14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/humupd\/dmh012","volume":"10","author":"JC Carel","year":"2004","unstructured":"Carel JC, et al. Precocious puberty and statural growth. Hum Reprod Update. 2004;10(2):135\u201347.","journal-title":"Hum Reprod Update"},{"issue":"9","key":"1634_CR15","doi-asserted-by":"publisher","first-page":"4127","DOI":"10.1210\/jcem.86.9.7852","volume":"86","author":"L Lazar","year":"2001","unstructured":"Lazar L, et al. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab. 2001;86(9):4127\u201332.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7\u20138","key":"1634_CR16","first-page":"885","volume":"28","author":"A Zung","year":"2015","unstructured":"Zung A, et al. Monitoring gonadotropin-releasing hormone analogue (GnRHa) treatment in girls with central precocious puberty: a comparison of four methods. J Pediatr Endocrinol Metab. 2015;28(7\u20138):885\u201393.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"4","key":"1634_CR17","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1080\/09513590.2019.1655726","volume":"36","author":"S Lasorella","year":"2020","unstructured":"Lasorella S, et al. Comparison of triptorelin acetate vs triptorelin pamoate in the treatment of central precocious puberty (CPP): a retrospective study. Gynecol Endocrinol. 2020;36(4):338\u201340.","journal-title":"Gynecol Endocrinol"},{"issue":"34","key":"1634_CR18","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e219","volume":"36","author":"LY Chung","year":"2021","unstructured":"Chung LY, et al. Efficacy of triptorelin 3-month depot compared to 1-month depot for the treatment of Korean girls with central precocious puberty in single tertiary center. J Korean Med Sci. 2021;36(34):e219.","journal-title":"J Korean Med Sci"},{"issue":"7\u20138","key":"1634_CR19","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1080\/00365513.2022.2148120","volume":"82","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, et al. A single blood sample for stimulated LH assayed by ICMA is useful for monitoring the treatment efficacy of triptorelin depot in girls. Scand J Clin Lab Invest. 2022;82(7\u20138):588\u201394.","journal-title":"Scand J Clin Lab Invest"},{"issue":"2","key":"1634_CR20","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s12020-024-03781-9","volume":"85","author":"A Li Pomi","year":"2024","unstructured":"Li Pomi A, et al. Screening for central precocious puberty by single basal luteinizing hormone levels. Endocrine. 2024;85(2):955\u201363.","journal-title":"Endocrine"},{"issue":"5","key":"1634_CR21","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1210\/jc.2011-2704","volume":"97","author":"PA Lee","year":"2012","unstructured":"Lee PA, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012;97(5):1572\u201380.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1634_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1210\/js.2019-00036","volume":"3","author":"EA Eugster","year":"2019","unstructured":"Eugster EA. Treatment of central precocious puberty. J Endocr Soc. 2019;3(5):965\u201372.","journal-title":"J Endocr Soc"},{"issue":"6","key":"1634_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000501336","volume":"91","author":"K Bangalore Krishna","year":"2019","unstructured":"Bangalore Krishna K, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019;91(6):357\u201372.","journal-title":"Horm Res Paediatr"},{"key":"1634_CR24","unstructured":"Ferring Pharmaceuticals. Gonapeptyl Depot 3.75 mg \u2014 Summary of Product Characteristics (SmPC). 2023. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/gonapeptyl-depot-epar-product-information_en.pdf."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01634-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01634-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:07:34Z","timestamp":1781622454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01634-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01634-4","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kun Wang, Zhongyi Sun, Fengyan Xu, and Lu Liu served as consultants to Changchun GeneScience. Tianhong Luo, Weiwei Gao, Tangping Zhao, Guangli Ma and Xiaoyan Zhu are employees of Changchun GeneScience Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Kun Wang and Xiaoyan Zhu wrote the original manuscript. Tangping Zhao, Xiaoyan Zhu, and Guangli Ma conceptualized the research. Tianhong Luo and Weiwei Gao performed research. Kun Wang, Zongyi Sun, Fengyan Xu, and Lu Liu analyzed the data. All authors reviewed the key steps of the analysis, commented on intermediate versions of the manuscript, and read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"Individual trial protocols were approved by the Institutional Review Boards\/Ethics Committees of the study sites.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All participants gave written informed consent before participating in the respective studies","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analysed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}